Caffeine acutely modulates CGRP, NO, and endothelin-1 in migraine patients during ictal attacks
Background
Migraine is a debilitating neurovascular disorder characterized by complex interactions between trigeminovascular, endothelial, and neuroimmune pathways. Dysregulation of key mediators like calcitonin gene-related peptide (CGRP), nitric oxide (NO), endothelin-1, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) is central to its pathophysiology. While these mediators are implicated, their phase-dependent dynamics and acute responsiveness to common interventions like caffeine have remained largely undefined, presenting a critical gap in understanding migraine mechanisms and optimizing therapeutic strategies.
Study Design
This randomized, double-blind, placebo-controlled crossover study included 327 participants (174 migraine patients, 153 healthy controls). Migraine patients were assessed across interictal and ictal phases using a within-subject design. During ictal attacks, participants received a single oral dose of 200 mg caffeine or placebo. Blood samples were collected at baseline (T0) and 60 min post-intervention (T1). Mediator levels were quantified using ELISA and analyzed with linear mixed-effects models to evaluate phase-specific alterations and intra-individual responses to caffeine.
Results
Key neurovascular-immune mediators showed significant phase-dependent alterations in migraine patients. CGRP, NO, IL-6, and TNF-α were significantly elevated during migraine, particularly in the ictal phase, while endothelin-1 levels were reduced. Acute administration of caffeine demonstrated potent modulatory effects on these mediators during an attack. > Caffeine significantly decreased CGRP and NO levels and increased endothelin-1 compared with placebo, promoting a shift toward a more vasoconstrictive vascular balance and reduced trigeminovascular activation. IL-6 and TNF-α also showed modest, though less pronounced, reductions. The individual responses to caffeine varied, with greater effects observed in patients who presented with higher baseline levels of these mediators, underscoring the importance of individual physiological state.
Key Findings
- CGRP, NO, IL-6, and TNF-α were significantly elevated during migraine attacks.
- Endothelin-1 levels were reduced during migraine attacks.
- Acute 200 mg caffeine significantly decreased CGRP and NO levels vs. placebo.
- Acute 200 mg caffeine significantly increased endothelin-1 levels vs. placebo.
- Caffeine's effects were greater in individuals with higher baseline mediator levels.
Why It Matters
This study provides crucial insights into the dynamic interplay of neurovascular and inflammatory mediators in migraine and demonstrates that caffeine can acutely modulate these pathways. The finding that caffeine shifts vascular balance towards vasoconstriction and reduces trigeminovascular activation offers a mechanistic explanation for its known efficacy in acute migraine treatment. This suggests that caffeine could be a valuable acute intervention or adjunct, particularly for individuals with elevated baseline CGRP or NO. The emphasis on state-dependent responsiveness highlights the need for individualized approaches in migraine management, potentially guiding more targeted therapeutic strategies based on a patient's current mediator profile.
migraine
caffeine
cgrp
nitric-oxide
endothelin-1
neuroinflammation